We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
SCNX

Price
0.91
Stock movement down
-0.05 (-4.66%)
Company name
Scienture Holdings, Inc.
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Pharmaceutical Retailers
Market cap
19.75M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-87.81%
3 year return
-62.98%
5 year return
-59.25%
10 year return
-25.26%
Last updated: 2025-09-15

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

SCNX does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.08
Daily high1.08
Daily low0.81
Daily Volume416K
All-time high119.40
1y analyst estimate-
Beta-
EPS (TTM)-
Dividend per share-
Ex-div date19 Jul 2024
Next earnings date-

Downside potential

Loading...
Downside potential data
SCNXS&P500
Current price drop from All-time high-99.15%-1.46%
Highest price drop-99.83%-56.47%
Date of highest drop5 Feb 20149 Mar 2009
Avg drop from high-73.21%-10.99%
Avg time to new high40 days12 days
Max time to new high1442 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
SCNX (Scienture Holdings, Inc.) company logo
Marketcap
19.75M
Marketcap category
Small-cap
Description
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is based in Tampa, Florida.
Employees
14
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner